Phase II Study of an Omega-3 Fatty Acid in TNBC Survivors
Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
Clinical Pearls
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
- This phase II study looks to analyze whether DHA, an omega-3 fatty acid, will reduce circulating markers of inflammation in overweight/obese patients with a history of TNBC
- In another poster, it was hypothesized that targeting the inflammation-aromatase axis with an omega-3 fatty acid could decrease the risk for relapse or development of breast cancer
- This trial will look at breast tissue pre- and post-intervention to determine if there is a decreases in inflammatory markers after 3 months of treatment with the omega-3 fatty acid
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Subcutaneous Daratumumab Significantly Delays Progression in Smoldering Myeloma
December 9th 2024Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS compared with active monitoring in patients with smoldering multiple myeloma.
Read More
